clinical trial · NCT07850739
Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH)
Congenital Adrenal HyperplasiaNBIP-01435
brief summary
The main objective of this study is to evaluate the efficacy of different dose levels of NBIP-01435 on reducing elevated androstenedione (A4) levels in adults with classic CAH.
started
Dec 1, 2026
primary completion
Mar 16, 2028
completion
May 11, 2028
last updated
Sep 30, 2026
official title
A Phase 2, Open-Label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adults With Classic Congenital Adrenal Hyperplasia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol